2023 Annual Report

During 2023 we achieved profitability while intensively investing in the development of our late-stage assets and the scale-up of our commercial infrastructure and marketing activity. This has resulted in Telix capturing a meaningful market share in the growing urology imaging market whilst laying the foundation for our next commercial products.

Download Report

Message from Chairman

"Telix has built a strong foundation as a diversified business and demonstrated our ability to capture this opportunity. We have an extensive clinical-stage pipeline of first-in-class or best-in-class therapeutic assets validated by clinical data, a specialist and proven commercial team, and have commenced the vertical integration of our supply chain and manufacturing activities."

Read more

Message from CEO

“We have continued to make significant progress across our extensive and highly differentiated clinical-stage therapeutic pipeline, dosing patients in our core therapy programs in prostate, kidney and brain cancer, whilst preparing to launch new studies in bone marrow conditioning and soft tissue sarcoma. The progress made in 2023 sets the stage for multiple catalysts and readouts in 2024.”

Read more